AG
NBIX icon

Advisor Group’s Neurocrine Biosciences NBIX Stock Holding History

Advisor Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$233K Sell
2,171
-306
-12% -$32K ﹤0.01% 2272
2019
Q3 		$224K Sell
2,477
-560
-18% -$52.3K ﹤0.01% 2231
2019
Q2 		$255K Buy
3,037
+459
+18% +$37.7K ﹤0.01% 2119
2019
Q1 		$227K Sell
2,578
-42
-2% -$3.51K ﹤0.01% 2180
2018
Q4 		$187K Sell
2,620
-11,722
-82% -$1.12M ﹤0.01% 2139
2018
Q3 		$1.76M Buy
14,342
+13,063
+1,021% +$1.48M 0.02% 700
2018
Q2 		$125K Sell
1,279
-235
-16% -$21K ﹤0.01% 2348
2018
Q1 		$125K Buy
1,514
+1,404
+1,276% +$119K ﹤0.01% 2370
2017
Q4 		$9K Sell
110
-1,404
-93% -$95.8K ﹤0.01% 4146
2017
Q3 		$92K Buy
1,514
+1,109
+274% +$58.5K ﹤0.01% 2479
2017
Q2 		$18K Sell
405
-821
-67% -$39.8K ﹤0.01% 3563
2017
Q1 		$53K Buy
1,226
+1,200
+4,615% +$51.4K ﹤0.01% 2656
2016
Q4 		$1K Sell
26
-161
-86% -$7.29K ﹤0.01% 4374
2016
Q3 		$9K Buy
187
+57
+44% +$2.84K ﹤0.01% 3622
2016
Q2 		$4K Buy
+130
New +$5.99K ﹤0.01% 3882

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Advisor Group's NBIX Position: Q4 2019 in Review

Advisor Group reduced its Neurocrine Biosciences (NBIX) stake by 12% in Q4 2019, selling an estimated $32K and leaving 2,171 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Advisor Group first reported a position in NBIX in Q2 2016 and has held it in 15 quarters since. The position peaked at $1.76M in Q3 2018. 391 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Advisor Group held 2,171 shares of Neurocrine Biosciences worth $233K as of Q4 2019.
  • Advisor Group sold 306 Neurocrine Biosciences shares in Q4 2019, an estimated $32K.
  • Neurocrine Biosciences made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2272 holding.
  • Advisor Group first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Neurocrine Biosciences position peaked at $1.76M in Q3 2018.
  • 391 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.